Aspects épidémiologiques des cancers de l'enfant, Rev Prat, vol.64, issue.9, pp.1264-1273, 2014. ,
Preclinical studies and clinical correlation of the effect of alkylating dose, Cancer Res, vol.48, issue.22, pp.6417-6440, 1988. ,
Busulfan conjugation by glutathione Stransferases alpha, mu, and pi, Drug Metab Dispos Biol Fate Chem, vol.24, issue.9, pp.1015-1024, 1996. ,
,
, Pharmacokinetic and metabolic studies of high-dose busulphan in adults, Eur J Clin Pharmacol, vol.36, issue.5, pp.525-555, 1989.
Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression, Pharmacogenetics, vol.11, issue.8, pp.663-672, 2001. ,
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa), Bone Marrow Transplant, vol.32, issue.10, pp.979-86, 2003. ,
Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation, Pediatr Transplant, vol.7, issue.3, pp.12-20, 2003. ,
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics, Cancer Chemother Pharmacol, vol.33, issue.3, pp.181-187, 1993. ,
The role of busulfan in bone marrow transplantation, Med Oncol Northwood Lond Engl, vol.16, issue.3, pp.166-76, 1999. ,
Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother Pharmacol, vol.25, issue.1, pp.55-61, 1989. ,
Chronopharmacology of high-dose busulfan in children, Cancer Res, vol.53, issue.7, pp.1534-1541, 1993. ,
Busulfan disposition in children, Blood, vol.75, issue.8, pp.1723-1730, 1990. ,
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology, Cancer Chemother Pharmacol, vol.28, issue.2, pp.130-134, 1991. ,
Disposition of high-dose busulfan in pediatric patients undergoing bone marrow transplantation, Clin Pharmacol Ther, vol.54, issue.1, pp.45-52, 1993. ,
Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood, vol.79, pp.2475-2484, 1992. ,
Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.8, issue.3, pp.145-54, 2002. ,
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.8, issue.9, pp.477-85, 2002. ,
Association of busulfan area under the curve with veno-occlusive disease following BMT, Bone Marrow Transplant, vol.17, issue.2, pp.225-255, 1996. ,
Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation, Bone Marrow Transplant, vol.28, issue.11, pp.1013-1021, 2001. ,
busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients, Bone Marrow Transplant, vol.33, issue.10, pp.979-87, 2004. ,
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring, Cancer Chemother Pharmacol, vol.61, issue.1, pp.113-136, 2008. ,
,
, Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer, vol.58, pp.90-97, 2012.
The syndrome of hepatic veno-occlusive disease after marrow transplantation, Blood, vol.85, issue.11, pp.3005-3025, 1995. ,
Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients, Ann Intern Med, vol.118, issue.4, pp.255-67, 1993. ,
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.16, issue.2, pp.157-68, 2010. ,
,
, Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation, J Clin Oncol Off J Am Soc Clin Oncol, vol.11, issue.9, pp.1729-1765, 1993.
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children, Bone Marrow Transplant, vol.10, issue.2, pp.135-176, 1992. ,
,
, Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stemcell transplantation: an open-label, phase 3, randomised controlled trial, Lancet Lond Engl, vol.379, issue.9823, pp.1301-1310, 2012.
Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party, Blood, vol.92, issue.10, pp.3599-604, 1998. ,
Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatol Baltim Md, vol.4, pp.116-138, 1984. ,
BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation, Br J Haematol, vol.163, issue.4, pp.444-57, 2013. ,
Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide, Bone Marrow Transplant, vol.38, issue.8, pp.547-53, 2006. ,
Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving highdose myeloablative chemotherapy for high-risk neuroblastoma as ,
, Eur J Cancer Oxf Engl, vol.48, issue.16, pp.3063-72, 1990.
Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a singlecenter report of 48 patients, Pediatrics, vol.117, issue.4, pp.743-750, 2006. ,
Hepatobiliary complications of hematopoietic cell transplantation, 40 years on. Hepatol Baltim Md, vol.51, pp.1450-60, 2010. ,
Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease, Transplantation, vol.74, issue.1, pp.60-66, 2002. ,
,
, Venoocclusive disease of the liver following bone marrow transplantation, Transplantation, vol.44, issue.6, pp.778-83, 1987.
On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease, Ann Hematol, vol.66, issue.2, pp.77-80, 1993. ,
Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation, Bone Marrow Transplant, vol.53, issue.2, pp.138-183, 2018. ,
Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial, Ann Intern Med, vol.128, issue.12, pp.975-81, 1998. ,
,
, Rev Mal Respir, vol.35, issue.2, pp.160-70, 2018.
Pulmonary Veno-Occlusive Disease, Circulation, vol.34, issue.2, pp.242-250, 1966. ,
Late-onset noninfectious interstitial lung disease after allogeneic hematopoietic stem cell transplantation, Respir Med, vol.108, issue.10, pp.1525-1558, 2014. ,
Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation, Bone Marrow Transplant, vol.33, issue.7, pp.751-759, 2004. ,
Long-term pulmonary sequelae after autologous bone marrow transplantation in children without total body irradiation, Bone Marrow Transplant, vol.16, issue.6, pp.771-776, 1995. ,
Late-onset noninfectious interstitial lung disease following autologous haematopoietic stem cell transplantation in paediatric patients, Respirol Carlton Vic, vol.21, issue.6, pp.1068-74, 2016. ,
Nonbacterial nonfungal interstitial pneumonitis following autologous bone marrow transplantation in children treated with high-dose chemotherapy without total-body irradiation, Transplantation, vol.45, issue.4, pp.737-777, 1988. ,
Pathologic assessment of vasculopathies in pulmonary hypertension, J Am Coll Cardiol, vol.43, issue.12, pp.25-32, 2004. ,
The pathology of pulmonary veno-occlusive disease, Virchows Arch A Pathol Anat Histol, vol.364, issue.1, pp.69-79, 1974. ,
Human alveolar capillaries undergo angiogenesis in pulmonary veno-occlusive disease, Eur Respir J, vol.9, issue.2, pp.346-50, 1996. ,
,
, Chemotherapy-induced pulmonary hypertension: role of alkylating agents, Am J Pathol, vol.185, issue.2, pp.356-71, 2015.
,
, Mitomycin-Induced Pulmonary Veno-Occlusive Disease: Evidence From Human Disease and Animal Models, Circulation, vol.132, issue.9, pp.834-881, 2015.
Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease, Eur Respir J, vol.46, issue.6, pp.1721-1752, 2015. ,
Pulmonary venoocclusive disease, Eur Respir J, vol.47, issue.5, pp.1518-1552, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01514453
Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension, Eur Respir J, vol.35, issue.1, pp.6-8, 2010. ,
Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases, Hum Pathol, vol.38, issue.6, pp.893-902, 2007. ,
Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension, J Rheumatol, vol.33, issue.11, pp.2347-50, 2006. ,
Pulmonary veno-occlusive disease after bone marrow transplantation, Thorax, vol.39, issue.12, pp.956-963, 1984. ,
Malignancy-associated pulmonary veno-occlusive disease: report of a case following autologous bone marrow transplantation and review, Bone Marrow Transplant, vol.18, issue.4, pp.755-60, 1996. ,
Pulmonary hypertension associated with pulmonary occlusive vasculopathy after allogeneic bone marrow transplantation, Transplantation, vol.69, issue.1, pp.177-186, 2000. ,
Pulmonary venoocclusive disease following bone marrow transplantation, Transplantation, vol.47, issue.6, pp.989-92, 1989. ,
Pulmonary veno-occlusive disease after autologous bone marrow transplant in a child with stage IV neuroblastoma: case report and literature review, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, issue.1, pp.405-414, 2003. ,
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore), vol.87, pp.220-253, 2008. ,
Occult alveolar haemorrhage in pulmonary veno-occlusive disease, Eur Respir J, vol.27, issue.1, pp.108-121, 2006. ,
From the Archives of the AFIP: pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis, vol.27, pp.867-82, 2007. ,
Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease, AJR Am J Roentgenol, vol.183, issue.1, pp.65-70, 2004. ,
Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward, Eur Heart J, vol.32, issue.20, pp.2489-98, 2011. ,
Pulmonary veno-occlusive disease: a case series and new observations, Chest, vol.118, issue.6, pp.1671-1680, 2000. ,
Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary venoocclusive disease, Chest, vol.113, issue.1, pp.237-277, 1998. ,
ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT), Eur Respir J, vol.46, issue.4, pp.903-75, 2015. ,
Pulmonary venoocclusive disease, Eur Respir J, vol.33, issue.1, pp.189-200, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01514453
Pulmonary veno-occlusive disease, Am J Respir Crit Care Med, vol.162, issue.5, pp.1964-73, 2000. ,
Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy, Int J Radiat Oncol Biol Phys, vol.47, issue.1, pp.13-47, 2000. ,
,
, Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.21, pp.3516-3540, 2010.
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.3, pp.532-572, 2005. ,
NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology, J Clin Oncol Off J Am Soc Clin Oncol, vol.15, issue.12, pp.3433-3473, 1997. ,
Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.20, pp.3284-91, 2010. ,
Randomized Controlled Trial of Interval-Compressed Chemotherapy for the Treatment of Localized Ewing Sarcoma: A Report From the Children's Oncology Group, J Clin Oncol, vol.30, issue.33, pp.4148-54, 2012. ,
,
, High-dose busulfan-thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. Pediatr Blood Cancer, vol.61, pp.907-919, 2014.
Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children, Lancet Oncol, vol.6, issue.8, pp.573-80, 2005. ,
Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS), J Clin Oncol, vol.95, pp.8515-8515, 2004. ,
Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98, Eur J Cancer Oxf Engl, vol.46, issue.9, pp.1588-95, 1990. ,
Revisiting the role of doxorubicin in the treatment of rhabdomyosarcoma: an up-front window study in newly diagnosed children with high-risk metastatic disease, Eur J Cancer Oxf Engl, 1990. ,
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study, Eur J Cancer Oxf Engl, vol.88, pp.57-66, 1990. ,
URL : https://hal.archives-ouvertes.fr/inserm-01667245
Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis, Br J Haematol, vol.124, issue.1, pp.63-71, 2004. ,
Zur Histologie der klinischen "primären Pulmonalsklerose ,
The pathology of pulmonary veno-occlusive disease, Virchows Arch A Pathol Anat Histol, vol.364, issue.1, pp.69-79, 1974. ,
Pulmonary venoocclusive disease, Eur Respir J, vol.47, issue.5, pp.1518-1552, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01514453
,
, Pulmonary Veno-occlusive Disease: Clinical, Functional, Radiologic, and Hemodynamic Characteristics and Outcome of 24 Cases Confirmed by Histology. Medicine (Baltimore), 2008.
, Jul, vol.1, issue.4, pp.220-253
,
, Presse Medicale Paris Fr, vol.39, issue.1, pp.134-177, 1983.
,
, Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease, J Heart Lung Transplant, vol.37, issue.5, pp.647-55, 2018.
,
, Presse Medicale Paris Fr, vol.43, issue.9, pp.981-93, 1983.
Pulmonary Edema Complicating Continuous Intravenous Prostacyclin in Pulmonary Capillary Hemangiomatosis, Am J Respir Crit Care Med, vol.157, issue.5, pp.1681-1686, 1998. ,
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study, Lancet Respir Med, vol.5, issue.2, pp.125-159, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01436297
Sildenafil as Adjunct Therapy to High-Dose Epoprostenol in a Patient with Pulmonary Veno-Occlusive Disease, Heart Lung Circ, vol.15, issue.2, pp.139-181, 2006. ,
Effect of Prostacyclin on Microvascular Pressures in a Patient With Pulmonary Veno-Occlusive Disease, CHEST, vol.108, issue.6, pp.1754-1760, 1995. ,
Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution, Eur Respir J, vol.34, issue.5, pp.1204-1210, 2009. ,
EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension, Nat Genet, vol.46, issue.1, pp.65-74, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01514453